Roivant Sciences (NASDAQ: ROIV) net income
Roivant Sciences reported a net loss of $299.8m for fiscal 2026; in fiscal 2025 it reported a net loss of $172.0m. Earnings per share were −$0.43.
Roivant Sciences's best year of the last 6 was fiscal 2024. It reported a loss in 5 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2026 | −$299.8m | — | −3,629.2% | −$0.43 |
| 2025 | −$172.0m | −104.0% | −592.0% | −$0.24 |
| 2024 | $4,349m | — | 13,294.2% | $5.55 |
| 2023 | −$1,009m | — | −3,200.2% | −$1.42 |
| 2022 | −$845.3m | — | −1,528.9% | −$1.26 |
| 2021 | −$809.2m | — | −3,400.9% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Roivant Sciences net income compared with its sector
By net income for its latest fiscal year, Roivant Sciences ranks 448th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Roivant Sciences, −3,629.2%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 446th | Minerva Neurosciences | −$293.4m | — |
| 447th | Vera Therapeutics | −$299.6m | — |
| 448th | Roivant Sciences | −$299.8m | −3,629.2% |
| 449th | Praxis Precision Medicines | −$303.3m | — |
| 450th | Kymera Therapeutics | −$311.4m | −794.0% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Roivant Sciences
- How much did Roivant Sciences earn in fiscal 2026?
- Roivant Sciences reported a net loss of $299.8m for fiscal 2026. In fiscal 2025 it reported a net loss of $172.0m.
- What are the earnings per share of Roivant Sciences?
- They were −$0.43 in fiscal 2026, compared with −$0.24 in fiscal 2025.
- What was the most profitable year for Roivant Sciences?
- Of its last 6 fiscal years, fiscal 2024, with $4,349m.
- Where does Roivant Sciences rank in its sector by net income?
- It ranks 448th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Roivant Sciences come from?
- From the annual report (Form 10-K) that Roivant Sciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Roivant Sciences files with the SEC. The filing for each fiscal year: 2026 · 2025 · 2024 · 2023 · 2022 · 2021. More on Roivant Sciences: the Roivant Sciences page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.